Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Quattro74on May 09, 2020 12:57pm

72 Views

Post# 31007098

RE:RE:RE:RE:RE:TLT

I'll be ok with a little more dilution as long as it is at much higher share price.

anabelsi wrote:

Yeah, the device devision should have been sold off ages ago and the focus should have been entirely on their cancer division. It has been nothing but waste for all these years!

How TLT brands themselves is also just dumb honestly. Look at their site:
https://theralase.com/

Cancer is mentioned twice on the home page, everything else is about their lasers and main parts of the page mention nothing but their laser devices - no real mention of their cancer devision, no mention of their successes or the current trials.

While the research team is great, management sure isn't. Either way, they now have more than enough cash to fully fund the trial. I swear if they dilliute again management should be fired.